Mithra Pharmaceuticals - Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator)
May 12, 2023 11:45 ET
|
Mithra Pharmaceuticals
Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator) Liege, Belgium, 12 May 2023 – 17:50 CET – Mithra Pharmaceuticals SA...
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients
May 11, 2023 01:30 ET
|
Mithra Pharmaceuticals
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients Trial designed to address limited clinical data in this population despite widespread use of Combined...
Mithra and the University of Liège Secure Proof-of-Concept for Novel Manufacturing Process of Estetrol
May 04, 2023 01:30 ET
|
Mithra Pharmaceuticals
Collaboration demonstrates Mithra’s commitment to innovation and sustainable drug supply in Women’s Health Liege, Belgium, 04 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company...
Publication of a transparency notification received from Alychlo NV
April 28, 2023 11:45 ET
|
Mithra Pharmaceuticals
Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007...
Mithra Releases Invitation to its General Shareholders’ Meeting
April 25, 2023 01:30 ET
|
Mithra Pharmaceuticals
Mithra Releases Invitation to its General Shareholders’ Meeting Liege, Belgium, 25 April 2023 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces...
Mithra Reports Full Year 2019 Financial Results
March 09, 2020 02:30 ET
|
Mithra Pharmaceuticals
Record revenue (EUR 96.5 million) and EBITDA (EUR 40.7 million) increased respectively by 47% and 6%, mainly driven by U.S. deal for Estelle®Anticipated future licensing milestones for Estelle®...
E4 Paves the Road Towards a Revolutionary Era of Environmental Friendly Medicines
January 10, 2020 01:30 ET
|
Mithra Pharmaceuticals
Estelle® to be the 1st Combined Oral Contraceptive (COC) based on an environmental friendly estrogen (E4)Environmental Risk Assessment study demonstrates absence of environmental risk for Estetrol...
Mithra Signs Landmark Contract for Estelle® in the United States With Mayne Pharma
October 01, 2019 07:15 ET
|
Mithra Pharmaceuticals
Historical agreement with Mayne Pharma, who became the second largest supplier of oral contraceptives in the US after the acquisition of a portfolio of branded generic products from TEVA in...
Mithra annonce ses résultats annuels 2018
March 01, 2019 07:00 ET
|
Mithra Pharmaceuticals
Mithra annonce ses résultats annuels 2018 Forte croissance du chiffre d'affaires (+42%) et amélioration significative de l'EBITDA qui atteint un niveau record (38,3 millions EUR contre -18,4...
Mithra Reports 2018 Annual Results
March 01, 2019 07:00 ET
|
Mithra Pharmaceuticals
Mithra Reports 2018 Annual Results Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M...